Dr. Rolando’s research addresses a common challenge in human health: the inability to diagnose diseases early enough for effective treatment, especially when symptoms are latent or non-specific. Using liquid biopsy and longitudinal studies of human health, he seeks to diagnose nascent diseases. Specifically, using quantitative state-of-the-art single-molecule protein-based and nucleic acid-based diagnostic tools (e.g., SIMOA, LAMP, and CRISPR), predictive machine learning models, clinical imaging, and novel biomarkers, Justin uncovers the molecular mechanisms of how molecular heterogeneity leads to overarching organism-level phenomena like pediatric sepsis, breast cancer, and antimicrobial resistance. When developed further, the quantitative pathophysiological research from his teams identify fingerprints of disease, paving the way for reduced human morbidity and mortality through in vitro diagnostic systems.